{"id":290872,"date":"2026-10-07T09:19:22","date_gmt":"2026-10-07T03:49:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=290872"},"modified":"2026-10-07T09:19:22","modified_gmt":"2026-10-07T03:49:22","slug":"newly-listed-pharma-stocks-strong-roadmap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/newly-listed-pharma-stocks-strong-roadmap\/","title":{"rendered":"3 Newly Listed Pharma Stocks With a Strong Future Roadmap: Corona Remedies, Rubicon Research and Kwality Pharmaceuticals"},"content":{"rendered":"

Corona Remedies Rs 2,038.30, P\/E 62.62. Rubicon Research Rs 1,596.80, P\/E 91.75. Kwality Pharma Rs 3,745.00, P\/E 48.02. Closing prices of 6 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Newly listed pharma stocks with the clearest long-term roadmaps today include Corona Remedies in branded formulations for chronic and acute therapies in India, Rubicon Research in specialty and complex generic formulations for the United States and Kwality Pharmaceuticals in oncology, hormone and other formulations for export markets. FY26 revenue growth was 17.6% at Corona Remedies, 36.8% at Rubicon Research and 36.0% at Kwality Pharma. P\/E stands at 62.62 for Corona Remedies (industry 37.19), 91.75 for Rubicon Research (industry 37.19) and 48.02 for Kwality Pharma (industry 37.19). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Newly listed pharma stocks give investors exposure to recent IPO companies that sell branded formulations, specialty generics and export products. Results depend on product launches, prescription growth and operating margin, which is why a visible track record matters as much as headline growth.<\/p>\n

This list covers three specialty formulation stocks: Corona Remedies for branded formulations for chronic and acute therapies in India, Rubicon Research for specialty and complex generic formulations for the United States and Kwality Pharmaceuticals for oncology, hormone and other formulations for export markets. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n